Results 201 to 210 of about 108,157 (279)
Author Reply: ‘Is lung function in a race against time?’
Experimental Physiology, EarlyView.
Bredan Cooper, Sanja Stanojevic
wiley +1 more source
Abstract Transitions of care are the movement of a patient from one care setting or provider to another. Interprofessional collaboration is critical in ensuring patient safety and satisfactory health outcomes. Each time an interprofessional team transfers a patient, the team performs three important roles: representing the patient, providing patient ...
Sara Edwards +9 more
wiley +1 more source
Lower lobe mucus plug distribution and future respiratory exacerbations in tobacco-exposed individuals with and without COPD. [PDF]
Wan ES +15 more
europepmc +1 more source
ABSTRACT Background and Purpose Individuals with chronic respiratory conditions have physical impairments that lead to disability, but which can be alleviated with physical exercise. We aimed to examine the responsiveness and interpretability of the World Health Organisation Disability Assessment Schedule (WHODAS) 2.0 following an exercise‐based ...
Chayenne Chylld César Lopes +3 more
wiley +1 more source
Classification of pulmonary diseases using machine learning and deep learning models on GLI-2012 standardized spirometry features. [PDF]
Koca YB.
europepmc +1 more source
ABSTRACT Background and Purpose Chronic Obstructive Pulmonary Disease (COPD) is a pulmonary condition characterized by airflow obstruction, which progresses with systemic alterations such as changes in muscle composition and metabolism, anticipating the activation of the inspiratory metaboreflex.
Natália Mota da Silva Borges +19 more
wiley +1 more source
Impulse oscillometry and traditional pulmonary function testing: correlation, advances and clinical implications. [PDF]
Yao S +5 more
europepmc +1 more source
ABSTRACT Nintedanib, a multitargeted tyrosine kinase inhibitor, is approved for idiopathic pulmonary fibrosis (IPF) for its ability to slow lung function decline. This study systematically evaluated the effects of nintedanib across three independent treatment intervention studies in the single‐dose bleomycin (BLEO) mouse model of IPF.
Jamal Bousamaki +12 more
wiley +1 more source

